3 New Strong Buy Ratings from Top-Rated Analysts: 07/22/2026

Most investors have never heard of these names … Yet they have very high potential. Let’s get to ‘em:

• InfuSystem Holdings (INFU): Affordable stock with BIG upside targets
• Neurocrine Biosciences (NBIX): 18 analysts bullish, zero say sell
• Tapestry (TPR): Coach's parent could climb over 60%

P.S. Speaking of stocks to check out today … Check out these.

A note from our sponsors...

The Core of a Winning Portfolio

The 7 Stocks to Buy and Hold Forever aren't just plays for the next quarter – they're built to deliver for decades. These are blue-chip companies with fortress balance sheets, elite dividend track records, and the staying power to outperform in bull and bear markets alike. Some are Dividend Kings, others are on the path there, and all are proven wealth compounding machines. Whether you're after steady income, capital growth, or both, this is the list long-term investors will want in their back pocket.

Download the full list now – before it disappears behind the paywall.

1. Infusystem Holdings (NYSEMKT: INFU)

This health services company is benefiting from improved treatment volumes in its patient services business and growing sales of medical equipment, positioning it as the highest-rated stock in the Medical industry with substantial upside potential.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $8.94 — get current quote

Max 1-year forecast: $15.00

Why we're watching:

• INFU has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
• For example, Roth Capital researcher Kyle Bauser (a top 19% rated analyst) reiterated his Strong Buy rating with a price target suggesting nearly 70% upside potential from current levels.
• Industry ranking context: INFU is currently the #2 highest-rated stock in the Medical industry, which has an Industry Rating of B.
• Zen Ratings highlights: INFU earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks with this rating have historically delivered nearly 30% annual returns, significantly outperforming the broader market.
• Component Grades: INFU excels with outstanding As for Financials and Sentiment, reflecting the company's strong execution and positive analyst outlook, while also maintaining solid Bs for Safety and Value, a combination that suggests favorable risk-adjusted return potential. See all 7 Component Grades here

2. Neurocrine Biosciences (NASDAQ: NBIX)

With a robust pipeline and strong financial performance, this pharma company is attracting broad analyst support as it continues to expand its market presence in specialized therapeutic areas.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $175.48 — get current quote

Max 1-year forecast: $246.00

Why we're watching:

• NBIX has strong, bullish coverage among the analysts we track, with 9 Strong Buy, 7 Buy, and 2 Hold recommendations. See all recommendations here
• For example, Wells Fargo researcher Mohit Bansal (a top 13% rated analyst) recently maintained his Strong Buy rating with a price target suggesting the stock could see close to 20% upside in the coming year. 
• Separately, Truist Securities researcher Danielle Brill (a top 10% rated analyst) maintained her Strong Buy with a similar price target.
• Industry ranking context: NBIX is currently the #2 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of C.
• Zen Ratings highlights: NBIX earns an overall A rating, which is a Strong Buy recommendation. This designation reflects the company's passage of a rigorous 115-factor fundamental analysis, placing it in the elite upper echelon of tracked equities.
• Component Grades: NBIX excels with exceptional A for Artificial Intelligence highlighting the company's strategic positioning in AI-driven drug development and attractive valuation metrics, while also earning strong Bs for Financials, Value, and Growth. See all 7 Component Grades here

3. Tapestry (NYSE: TPR)

You might not recognize the name Tapestry, but you probably know some of its brands: Coach, Kate Spade, and Stuart Weitzman. The company is demonstrating strong execution across its premium brand portfolio, with analysts citing robust earnings growth potential and market share expansion opportunities in the luxury segment.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $141.41 — get current quote

Max 1-year forecast: $230.00

Why we're watching:

• TPR has broad, bullish coverage among the analysts we track, with 8 Strong Buy and 3 Buy recommendations. See all recommendations here
• For example, Barclays researcher Adrienne Yih (a top 3% rated analyst) recently maintained her Strong Buy rating with a price target suggesting the stock could see nearly 30% upside in the coming year.
• Even more impressive in terms of upside potential, UBS researcher Jay Sole (a top 7% rated analyst) maintained his Strong Buy with a target that suggests the stock could see roughly 60% upside in the coming year.
• Industry ranking context: TPR is currently the #2 highest-rated stock in the Luxury industry, which has an Industry Rating of A.
• Zen Ratings highlights: TPR earns an overall A rating, which amounts to a Strong Buy recommendation. This places the stock among the top 5% of all equities tracked following a comprehensive fundamental review across 115 distinct factors.
• Component Grades: TPR excels with an outstanding A for Financials, reflecting the company's exceptional profitability and operational efficiency in the luxury goods sector, while maintaining solid Bs for Artificial Intelligence, Growth, and Sentiment. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.